

MEXICO – The Novartis pharmaceutical company reported that authorization was obtained from health officials to sell a drug to combat metastatic breast cancer (that extends to other parts of the body), which would allow a survival of up to five years.
In a press conference the general director of Novartis Oncology, Miguel Gallero, and medical specialists, highlighted the benefits of this drug that obtained the sanitary registry in November and will be available in the first third of 2018.
Gallero informed that Novartis invested nine billion dollars in 2016, worldwide, to promote the research of various molecules to continue the development of innovative medicines, such as the one called Ribociclib.
He added that precisely with the support of these innovative medicines, treatments are offered that give hope to patients to extend their life with quality, even to incorporate them into their daily tasks.

He indicated that 60% to 80 % of metastatic cancer in Mexico is diagnosed in locally advanced stages, however, with the application of new treatments, 81% of patients in stage four, which is among the most advanced, achieves five-year survival.
Meanwhile, the medical director of Novartis Oncology, Guillermina Muñoz, said that the treatments that this international laboratory has developed have revolutionized the context of patients with metastatic breast cancer in the world.
She highlighted that by doing research on the molecule that gives rise to Ribociclib, the increase, almost double, of progression-free survival, which allows a better quality of life, was demonstrated.
She explained that after two years of treatment, the combination of Ribociclib plus Letrozole increased the percentage of progression-free survival to 54.7%, compared with 35.9% in patients treated only with Letrozole.
The psychologist Alejandra Platas, of the Doctors and Researchers Foundation in the Fight against Breast Cancer (MILC), pointed out that 50 percent of the cases of advanced cancer in Mexico do not receive treatment when they face chronic pain, reason why she considered that it requires more prevention actions.
Source: www.yucatan.com.mx/health/
Comments
more recommended stories
Mauricio Vila reviews the latest details of the ‘La Plancha’ project
After managing the use of the.
Fatal accidents involving motorcyclists increase in Yucatan
Freddy Cetina Amaya, leader of the.
32-year-old patient dies from Covid in Yucatan
In Yucatan, the mandatory use of.
Yucatan is the state with the highest index of peace in all of Mexico
For having the lowest rates at.
Yucatan is present at the Tianguis Turístico 2022
Governor Mauricio Vila Dosal attended the.
Invasion and massive destruction of mangroves in Chicxulub Puerto
Inhabitants of Chicxulub Puerto ask to.
Title 42 has empowered U.S. agents to turn back over one million migrants to Mexico and other countries
For thousands of migrants who have.
Progreso Marinas report an increase of up to 30 percent in port departures
Yucatan commercial marinas reported an increase.
Environmental Impact studies for the Maya Train will be submitted for public consultation
The Environmental Impact Statement (MIA) of.
The Jurassic Trail aims to be an economic trigger for the port of Progreso
The Jurassic Trail continue with the.
Leave a Comment